Cryopreserved Platelets (CPP) for US FDA Licensure HT9427-26-RFI-705
Summary
AI-generated · Apr 24, 2026Defense Health Agency seeks to identify commercial partners capable of developing and managing Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen biologic-platelet product, to support Warfighter readiness and sustainment in operational environments, with collaboration through OPMED’s WPAC PMO toward FDA licensure.
DMSO CPP are expected to provide a platelet-derived product with a shelf life of about two years or longer, far exceeding liquid-stored platelets (LSP), which are licensed for 5–7 days at room temperature (20–24 C) under gentle agitation. The effort centers on industry capabilities for development and manufacturing of a long-life platelet product and the regulatory pathway toward licensure.
Defense Health Agency seeks to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation. We develop, directly through collaboration with commercial partners, medical products that enhance readiness and improve the quality of life of active-duty personnel in the operational environment. OPMED s WPAC PMO has been developing a biologic product: Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen, biologic-platelet product. DMSO CPP are formulated to provide a platelet-derived product with a longer shelf life (2 years and potentially longer) than liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20C to 24C) under gentle agitation.
From Sources Sought posted on Apr 23, 2026Notice history
1-
Sources Sought LATEST Posted Apr 23, 2026
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA